We serve Chemical Name:adipic acid heptylnonyl ester CAS:68515-75-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:adipic acid heptylnonyl ester
CAS.NO:68515-75-3
Synonyms:SANTICIZER97;hexanedioicacid,di-c7-9-branchedandlinearalkylesters;HEPTYLNONYL ADIPATE;Hexandisure,Di-C7-9-verzweigte und lineare Alkylester;Einecs 271-105-9
Molecular Formula:C22H42O4
Molecular Weight:370.56600
HS Code:2918990090
Physical and Chemical Properties:
Melting point:7.49ºC (280.65 K)
Boiling point:363.3ºC at 760 mmHg
Density:0.93 g/cm3
Index of Refraction:1.448
PSA:52.60000
Exact Mass:370.30800
LogP:6.35420
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like SANTICIZER97 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Einecs 271-105-9 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Einecs 271-105-9 Use and application,hexanedioicacid,di-c7-9-branchedandlinearalkylesters technical grade,usp/ep/jp grade.
Related News: From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. adipic acid heptylnonyl ester manufacturer Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. adipic acid heptylnonyl ester supplier This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire. adipic acid heptylnonyl ester vendor This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire. adipic acid heptylnonyl ester factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.
